Downregulation of Foxc2 enhances apoptosis induced by 5-fluorouracil through activation of MAPK and AKT pathways in colorectal cancer

Yang,Chao; Cui,Xiaoxian; Dai,Xiaoqin; Liao,Wenting

doi:10.3892/ol.2016.4097

Downregulation of Foxc2 enhances apoptosis induced by 5-fluorouracil through activation of MAPK and AKT pathways in colorectal cancer

Authors:
- Chao Yang
- Xiaoxian Cui
- Xiaoqin Dai
- Wenting Liao
View Affiliations

Affiliations: Department of Pathology, School of Basic Medical Science, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: January 8, 2016 https://doi.org/10.3892/ol.2016.4097
Pages: 1549-1554

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The chemotherapy drug 5-fluorouracil (5-FU) is fundamental for the treatment of colorectal cancer (CRC); however, drug resistance to 5‑FU may occasionally occur. Abnormal expression of Forkhead box C2 gene (Foxc2) has been identified in several human cancers, but the role of Foxc2 in the progression of CRC remains unclear. The present study established a stable Foxc2‑short hairpin (sh)RNA cell line, which was confirmed by western blot analysis and quantitative polymerase chain reaction. The Foxc2‑shRNA cells were treated with 5‑FU and the cell viability was determined by an MTT assay. Western blot analysis was performed to investigate the signaling pathway involved in 5‑FU treatment. The present study identified that 5‑FU increased the percentage of apoptotic CRC cells among the Foxc2/RNA interference‑transfected cells compared with cells transfected with an empty vector. Therefore, the downregulation of Foxc2, induced by 5‑FU, may enhance apoptosis by the downregulation of apoptotic factors, including B cell lymphoma‑2 and pro‑caspase‑3, in Foxc2‑shRNA CRC cells. Furthermore, the mitogen‑activated protein kinase (MAPK) and phosphatidylinositide 3‑kinases/protein kinase B (PI3K/AKT) pathways were essential for the sensitization effect of Foxc2 to 5‑FU treatment. Overall, these findings reveal the mechanisms behind Foxc2 depletion and 5‑FU treatment of CRC and suggest that Foxc2 enhances resistance to apoptosis, induced by 5‑FU, through the activation of MAPK and P13K/AKT pathways, and may serve as a valuable clinical prognostic marker for CRC.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Hendon SE and DiPalma JA: U.S. practices for colon cancer screening. Keio J Med. 54:179–183. 2005. View Article : Google Scholar : PubMed/NCBI
3	Miura N, Wanaka A, Tohyama M and Tanaka K: MFH-1, a new member of the fork head domain family, is expressed in developing mesenchyme. FEBS Lett. 326:171–176. 1993. View Article : Google Scholar : PubMed/NCBI
4	Nishida N, Mimori K, Yokobori T, Sudo T, Tanaka F, Shibata K, Ishii H, Doki Y and Mori M: FOXC2 is a novel prognostic factor in human esophageal squamous cell carcinoma. Ann Surg Oncol. 18:535–542. 2011. View Article : Google Scholar : PubMed/NCBI
5	Hollier BG, Tinnirello AA, Werden SJ, Evans KW, Taube JH, Sarkar TR, Sphyris N, Shariati M, Kumar SV, Battula VL, et al: FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res. 73:1981–1992. 2013. View Article : Google Scholar : PubMed/NCBI
6	van der Heul-Nieuwenhuijsen L, Dits NF and Jenster G: Gene expression of forkhead transcription factors in the normal and diseased human prostate. BJU Int. 103:1574–1580. 2009. View Article : Google Scholar : PubMed/NCBI
7	Papanicolaou KN, Izumiya Y and Walsh K: Forkhead transcription factors and cardiovascular biology. Circ Res. 102:16–31. 2008. View Article : Google Scholar : PubMed/NCBI
8	Sano H, Leboeuf JP, Novitskiy SV, Seo S, Zaja-Milatovic S, Dikov MM and Kume T: The Foxc2 transcription factor regulates tumor angiogenesis. Biochem Biophys Res Commun. 392:201–206. 2010. View Article : Google Scholar : PubMed/NCBI
9	Kume T: Foxc2 transcription factor: A newly described regulator of angiogenesis. Trends Cardiovasc Med. 18:224–228. 2008. View Article : Google Scholar : PubMed/NCBI
10	Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Kanazawa T, Tanaka T, Konishi T, et al: Gene expression of mesenchyme forkhead 1 (FOXC2) significantly correlates with the degree of lymph node metastasis in colorectal cancer. Int Surg. 96:207–216. 2011. View Article : Google Scholar : PubMed/NCBI
11	Subramanya RD, Coda AB and Sinha AA: Transcriptional profiling in alopecia areata defines immune and cell cycle control related genes within disease-specific signatures. Genomics. 96:146–153. 2010. View Article : Google Scholar : PubMed/NCBI
12	Petrova TV, Karpanen T, Norrmén C, Mellor R, Tamakoshi T, Finegold D, Ferrell R, Kerjaschki D, Mortimer P, Ylä-Herttuala S, et al: Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat Med. 10:974–981. 2004. View Article : Google Scholar : PubMed/NCBI
13	Cui YM, Jiang D, Zhang SH, Wu P, Ye YP, Chen CM, Tang N, Liang L, Li TT, Qi L, et al: FOXC2 promotes colorectal cancer proliferation through inhibition of FOXO3a and activation of MAPK and AKT signaling pathways. Cancer Lett. 353:87–94. 2014. View Article : Google Scholar : PubMed/NCBI
14	Likhite N and Warawdekar UM: A unique method for isolation and solubilization of proteins after extraction of RNA from tumor tissue using trizol. J Biomol Tech. 22:37–44. 2011.PubMed/NCBI
15	Mani SA, Yang J, Brooks M, Schwaninger G, Zhou A, Miura N, Kutok JL, Hartwell K, Richardson AL and Weinberg RA: Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci USA. 104:10069–10074. 2007. View Article : Google Scholar : PubMed/NCBI
16	Hahn WC, Dessain SK, Brooks MW, King JE, Elenbaas B, Sabatini DM, DeCaprio JA and Weinberg RA: Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol. 22:2111–2123. 2002. View Article : Google Scholar : PubMed/NCBI
17	Liao WT, Wang X, Xu LH, Kong QL, Yu CP, Li MZ, Shi L, Zeng MS and Song LB: Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival. Cancer. 115:1507–1517. 2009. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Vara Fresno JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and González-Barón P: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
20	Massagué J: G1 cell-cycle control and cancer. Nature. 432:298–306. 2004. View Article : Google Scholar : PubMed/NCBI
21	Watanabe A, Suzuki H, Yokobori T, Altan B, Kubo N, Araki K, Wada S, Mochida Y, Sasaki S, Kashiwabara K, et al: Forkhead box protein C2 contributes to invasion and metastasis of extrahepatic cholangiocarcinoma, resulting in a poor prognosis. Cancer Sci. 104:1427–1432. 2013. View Article : Google Scholar : PubMed/NCBI
22	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
23	Liu JJ, Lin M, Yu JY, Liu B and Bao JK: Targeting apoptotic and autophagic pathways for cancer therapeutics. Cancer Lett. 300:105–114. 2011. View Article : Google Scholar : PubMed/NCBI
24	Denicourt C and Dowdy SF: Medicine. Targeting apoptotic pathways in cancer cells. Science. 305:1411–1413. 2004. View Article : Google Scholar : PubMed/NCBI
25	Hougardy BM, Maduro JH, van der Zee AG, Willemse PH, de Jong S and de Vries EG: Clinical potential of inhibitors of survival pathways and activators of apoptotic pathways in treatment of cervical cancer: Changing the apoptotic balance. Lancet Oncol. 6:589–598. 2005. View Article : Google Scholar : PubMed/NCBI
26	Kang MH and Reynolds CP: Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 15:1126–1132. 2009. View Article : Google Scholar : PubMed/NCBI
27	Rinn JL, Wang JK, Allen N, Brugmann SA, Mikels AJ, Liu H, Ridky TW, Stadler HS, Nusse R, Helms JA and Chang HY: A dermal HOX transcriptional program regulates site-specific epidermal fate. Genes Dev. 22:303–307. 2008. View Article : Google Scholar : PubMed/NCBI
28	Leonis MA, Thobe MN and Waltz SE: Ron-receptor tyrosine kinase in tumorigenesis and metastasis. Future Oncol. 3:441–448. 2007. View Article : Google Scholar : PubMed/NCBI
29	Tsuchiya T, Tsuno NH, Asakage M, Yamada J, Yoneyama S, Okaji Y, Sasaki S, Kitayama J, Osada T, Takahashi K and Nagawa H: Apoptosis induction by p38 MAPK inhibitor in human colon cancer cells. Hepatogastroenterology. 55:930–935. 2008.PubMed/NCBI
30	Mao JD, Wu P, Huang JX, Wu J and Yang G: Role of ERK-MAPK signaling pathway in pentagastrin-regulated growth of large intestinal carcinoma. World J Gastroenterol. 20:12542–12550. 2014. View Article : Google Scholar : PubMed/NCBI
31	Esmaeili MA, Farimani MM and Kiaei M: Anticancer effect of calycopterin via PI3K/Akt and MAPK signaling pathways, ROS-mediated pathway and mitochondrial dysfunction in hepatoblastoma cancer (HepG2) cells. Mol Cell Biochem. 397:17–31. 2014. View Article : Google Scholar : PubMed/NCBI
32	Chen JY, Zhang L, Zhang H, Su L and Qin LP: Triggering of p38 MAPK and JNK signaling is important for oleanolic acid-induced apoptosis via the mitochondrial death pathway in hypertrophic scar fibroblasts. Phytother Res. 28:1468–1478. 2014. View Article : Google Scholar : PubMed/NCBI